Introduction
============

*Giardia lamblia* (syn. *Giardia intestinalis*, *Giardia duodenalis*) is a flagellate protozoan which may be found infecting the human small intestine, causing a disease called giardiasis. The symptomatology of human giardiasis is extremely variable, many individuals have the asymptomatic form while some have abdominal pain, nausea, acute or chronic diarrhea -- which may last several months, malabsorption and weight loss.[@b1-btt-3-273]--[@b3-btt-3-273] The clinical impact seems to be stronger in the first three years of life and in undernourished or immunodeficient individuals.[@b4-btt-3-273] *G. lamblia* has often been pointed out as the cause of growth disorders among children,[@b3-btt-3-273] also with the presence and frequency of diarrhea, for as long as the infection lasts, and the opportunity of reinfection, all constituting essential factors behind children's physical and mental debilitation.[@b5-btt-3-273]

*G. lamblia* is found in mammals, including human beings, cats, dogs, beavers, and cattle. Giardiasis is transmitted by the ingestion of cysts present in food and water; water dissemination being easier due to cysts resistance to chlorination.[@b6-btt-3-273],[@b7-btt-3-273] Cysts are highly infectious to men. Human volunteers have been experimentally infected with as few as 10 cysts.[@b8-btt-3-273] These cysts may remain viable in the environment for up to three months under favorable conditions of temperature and humidity. Three aspects are important in the epidemiological context of the disease: the cysts' resistance to the environment, the amount of cysts eliminated by the patients, and the zoonotic aspect of the disease.[@b9-btt-3-273]

Epidemics, in developed countries, have been attributed to an inappropriate water treatment, to its contamination with human or animal feces, particularly in surface water collections and lakes.[@b9-btt-3-273] Direct transmission from person to person is another infection mechanism, particularly important in collective institutions, such as daycare centers and orphanages, among members of the same family, and between male homosexual partners.[@b10-btt-3-273] In these populations, giardiasis reaches epidemic levels. *G. lamblia* has a cosmopolitan distribution with an estimated number of 2.8 × 10^8^ cases of infections per year and is thus the most common intestinal parasite in humans in developed countries.[@b11-btt-3-273] In Asia, Africa, and Latin America, about 200 million people have symptomatic giardiasis with some 500,000 new cases reported each year.[@b12-btt-3-273] In those countries this disease should be observed carefully, for it contributes substantially to generating mentally and physically impaired adults.

Thompson and colleagues[@b13-btt-3-273] reviewed publications by several authors who reported genetic variations among *Giardia* samples isolated from human beings. Such differences are believed to significantly influence giardiasis epidemiology and control, particularly for host susceptibility, virulence, drug sensitivity, antigenicity, and *in vivo* and *in vitro* development.[@b5-btt-3-273] Although some advances have been observed in isolating and characterizing *Giardia* samples, there are few studies regarding this parasite\`s chemotherapy.[@b14-btt-3-273] Resistance to different drugs used in the treatment of this disease has been reported and the number of cases is likely to increase.[@b15-btt-3-273]--[@b17-btt-3-273]

A variety of chemotherapeutic agents such as 5-nitroimidazole compounds, quinacrine, furazolidone, paromomycin, benzimidazole compounds, nitazoxanide have been used in the therapy for giardiasis. Nevertheless, therapeutic regimens and therapy reviews are little explored. Most drugs used have considerable adverse effects and, most of the time, they are contraindicated.[@b18-btt-3-273]--[@b20-btt-3-273] Furthermore, *Giardia* seems to have a great ability to resist these agents.[@b17-btt-3-273],[@b19-btt-3-273],[@b21-btt-3-273],[@b22-btt-3-273]

In this context, the study of new chemotherapeutic agents plays a fundamental role -- along with the reviews of the actually used drugs -- in the rationale for treatment of giardiasis on the basis of more consistent data.

Many compounds have shown giardicidal activity in *in vivo* models or in animal models. In the present review, we have systematically addressed the main *in vitro* and *in vivo* studies and prospective trials in human population concerning the treatment of giardiasis.

Methodology
===========

This is a review of giardiasis treatment in which we analyze the quality of the studies published in the Medline, PubMed, and EMBASE databases from 1966 to September, 2008.

Concentrating only on studies published in English, for each class of study (see below), we looked up the following key words in various combinations: giardia, giardiasis, treatment, therapeutic, therapy, drug, medication, phytotherapy, and chemotherapy. In those studies performed in humans, we did not have an age limit and searched for children and adult patients.

The studies were divided into four classes. Group I: *in vitro* studies; group II: *in vivo* studies; group III: clinical trials, nonrandomized, controlled or not; group IV: randomized control trials (RCT), blinded or not.

Inclusion criteria
------------------

We included the following studies: *In vitro* studies consisting of studies that tested the sensitivity and efficacy of the drugs against *Giardia; In vivo* studies consisting of studies that tested the efficacy of drugs against *Giardia* in experimental animals; Nonrandomized clinical trials consisting of studies that tested the efficacy of drugs against *Giardia* in humans; Randomized controlled clinical trials (RCT) consisting of studies designed to compare the efficacy between different drugs, between drugs and placebo, or to compare different schemes of the same drug in humans. These studies were necessarily randomized and controlled, but not necessarily blinded.

This review was made using two independent reviewers following the same inclusion criteria for searching the articles simultaneously. After they were finished, the reviews were analyzed. Those articles showing up in two reviews were automatically included in the final analysis. The remaining nonconsensual studies were analyzed by a third reviewer for a final decision as to include or exclude an article after the discussion between the first two reviewers was exhausted.

Statistical analysis
====================

Data are presented as mean ± standard deviation (confidence interval \[CI\]), absolute numbers, or percentages. Comparisons between rates of cure of drugs were made using the chi-squared or the Student *t*-test methods. Only variables with p \< 0.05 were considered significant.

Main results
------------

In the initial search, 116 *in vitro* studies, 48 *in vivo* studies, 87 nonrandomized clinical trials, and 47 RCT were found. After selection for the inclusion criteria, 39 *in vitro* studies, nine *in vivo* studies, 23 nonrandomized clinical trials, and 34 RCTs remained ([Tables 1](#t1-btt-3-273){ref-type="table"}--[4](#t4-btt-3-273){ref-type="table"}).

In the 39 *in vitro* studies selected, 55 drugs were tested, 53 (96.4%) showed activity against giardia. Eighteen studies (46.2%) did not have comparative design with other drugs. Twenty-one studies (53.8%) compared activity between drugs: 11 (52.4%) compared activity between two drugs, and 10 (47.6%) compared activity between three or more drugs.

The most frequently tested drugs in *in vitro* studies were: metronidazole (nine studies, 16.4%), albendazole (five studies, 9.1%), furazolidone (four studies, 7.3%), azitromicyn, nitazoxanide, phenyl-carbamate derivatives, tinidazole, and kaempferol (two studies each, 3.6%). The other drugs had one study each ([Table 5](#t5-btt-3-273){ref-type="table"}).

In the nine *in vivo* studies selected in which nine drugs were tested, eight (88.9%) showed activity against *Giardia*. One of them compared the efficacy between two drugs (11.1%), and the remaining study tested just one drug ([Table 2](#t2-btt-3-273){ref-type="table"}).

Out of the 23 nonrandomized clinical trials, six studies (26.1%) had design to compare efficacy between drugs, three (13%) compared different schemes of the same drug, and three (13%) compared efficacy between one drug and placebo (nonrandomized). Eleven studies evaluated the effect of one drug without comparing either dosages or efficacy between drugs (see [Table 3](#t3-btt-3-273){ref-type="table"}).

Twelve drugs have been tested in the 23 nonrandomized clinical trials, with an average sample size of 83.3 ± 53.3 patients per study (confidence interval \[CI\] = 57.2 to 109.4). The mean general rate of cure (RC) per drug was 85.5% ± 16.7 (CI = 80.0 to 91.0). The most frequently tested drugs were: metronidazole (nine studies, 39.1%), tinidazole (seven studies, 30.4%), ornidazole, and quinacrine (three studies each, 13%), secnidazole, furazolidone, and berberine (two studies each, 8.7%) ([Table 7](#t7-btt-3-273){ref-type="table"}). In evaluating drug effectiveness, the following mean rates of cure were found: secnidazole (RC = 96% ± 2.8), ornidazole (RC = 93.6% ± 1.2), tinidazole (RC = 89.1% ± 8.8), quinacrine (RC = 85% ± 21.6), furazolidone (RC = 82% ± 14), and metronidazole (RC = 76.6% ± 20.6) ([Table 8](#t8-btt-3-273){ref-type="table"}). The metronidazole was the most studied and tested drug for the giardiasis treatment. This drug had greater efficacy in larger doses and in more prolonged regimes (5 to 10 days), and achieved a cure rate of 87% to 100% in these schemes ([Table 9](#t9-btt-3-273){ref-type="table"}).

Out of the 34 RCTs selected for analysis, 23 studies (67.6%) had design to compare efficacy between drugs, five (14.7%) compared different schemes of the same drug, and five (14.7%) compared efficacy between one drug and placebo (randomized). One study tested a drug without comparing it with any other drug or placebo. Eight studies (23.5%) were double-blind studies, five (62.5%) compared one drug with placebo, while three (37.5%) compared the efficacy between drugs.

Eighteen drugs were tested on the 34 RCTs. The average sample size was 98.9 ± 38.0 patients per study (CI = 83.7 to 114.1). The mean general rate of cure per drug was 83.0% ± 16.1 (CI = 78.4 to 87.6). Interestingly, the mean rate of cure of the placebo was 25%.

There was no significant difference either in the sample size/patient relationship or in the rate of cure observed between nonrandomized and RCTs studies (83.3 × 98.9 patients/study and 85.5% × 83.0%; p \> 0.05).

The most frequently tested drugs in RCTs were: metronidazole (21 studies, 61.8%), tinidazole (10 studies, 29.4%), albendazole (nine studies, 26.5%), mebendazole (eight studies, 23.5%), ornidazole, furazolidone, and nitazoxanide (three studies each, 8.8%) ([Table 10](#t10-btt-3-273){ref-type="table"}).

Among drugs showing greater effectiveness, the following mean rates of cure were found: ornidazole (RC = 97.6% ± 2.5), tinidazole (RC = 91.1% ± 6.3), metronidazole (RC = 81.5% ± 18.6), nitazoxanide (RC = 79.7% ± 1.8), and albendazole (RC = 73.4% ± 19.8) ([Table 11](#t11-btt-3-273){ref-type="table"}). According to the nonrandomized clinical trials, metronidazole was the drug most frequently studied and tested on the RCTs. Likewise, this drug had greater efficacy with larger doses and with more prolonged regimes (5 to 10 days), reaching cure rates of 89% to 97% with these schemes ([Table 12](#t12-btt-3-273){ref-type="table"}).

On the RCTs, tinidazole and ornidazole were the drugs which showed good efficacy using a single-dose scheme. Albendazole shown great variability in efficacy, not only in a single dose (RC = 50% to 97%), but also in prolonged regimes (RC = 62% to 90%).

The side effects were poorly described in the majority of studies in the nonrandomized control trials, and they ranged from none to 59%, although they were mild and transient. As in nonrandomized clinical trials, the prevalence of side effects were poorly described in the majority of RCTs studies, ranging from few or absent to 70%, and were also mild and transient.

Discussion
==========

In 1957, the Rhone-Poulenc laboratories synthesized 1-(β-hydroxyethyl)-2-methyl-5-nitroimidazole (metronidazole) by manipulating the chemical structure of 2-nitroimidazole[@b126-btt-3-273] and this proved to be a highly effective agent against *Trichomonas vaginalis* infections.[@b127-btt-3-273] In 1962, Darbon and colleagues[@b128-btt-3-273] reported that this could also be used in treatments against giardiasis. Thus, since it was discovered, metronidazole and other 5-nitroimidazoles -- such as secnidazole, ornidazole, and tinidazole -- are used by physicians to treat *G. lamblia* infections in addition to infections by other microorganisms. Nowadays, metronidazole is the most used drug to treat giardiasis worldwide; including in the USA.[@b129-btt-3-273] However, the number of new drugs is increasing.

Doing this review, we found out that there were a high number of studies regarding the giardiasis treatment, even with the methodology used in the present study. However, the quality of them was very poor, mainly regarding their primary goal, their design, and sample size; in addition to a great heterogeneity detected between studies.

In all categories of studies, 298 were initially included (*in vitro*, *in vivo*, nonrandomized clinical trials, and RCTs), which, after selection, comprised 105 studies -- representing 35.2% -- that constituted the sample for the analysis. It is important to point out that we used relatively liberal criteria to select the articles, and the search was done only in the most important databases, comprising journals with more restricted and rigorous publication criteria.

One hundred and sixteen references to *in vitro* studies were found, which comprised 39 (33.6%) studies that constituted the data bank for analysis. Based on this, 50 drugs were evaluated, 48 (96%) of which showing activity against Giardia. Most of these studies had design to compare drugs among themselves (53 %): 52.4% to compare two drugs, and 47.6% to compare three or more drugs.

Many of the studies with two or more drugs did not necessarily compare the efficacy between drugs, but just analyzed and described the activity of the drugs without comparing their efficacy.

Although the number of known drugs tested was larger, we found out that the most widely tested drugs were metronidazole, albendazole, and furazolidone, and that the new drugs were larger in number, each with few studies ([Table 5](#t5-btt-3-273){ref-type="table"}). In this context, several *in vitro* studies have been carried out in order to search for new substances with antigiardial activity. This way, many methods have been described aiming at determining the antigiardial activity of drugs *in vitro*.[@b4-btt-3-273],[@b19-btt-3-273],[@b64-btt-3-273],[@b130-btt-3-273]--[@b133-btt-3-273] However, some of these are laborious and require long and hard work; furthermore, they are very difficult to reproduce for they lack standardization.

In the initial search for new drugs with antigiardial activity, 48 *in vivo* studies were found but only nine (18.8%) constituted the data bank for analysis, according to the inclusion criteria. Ten drugs were tested in these studies, and eight (80%) were active against *Giardia*. The majority of studies did not compare drugs, but just tested the activity of one drug against *Giardia* ([Tables 2](#t2-btt-3-273){ref-type="table"} and [6](#t6-btt-3-273){ref-type="table"}).

Again, the various models used and the absence of standardized design, besides the heterogeneity of these studies, make the comparative analysis difficult. In this context, several *in vivo* experimental models have been proposed. They are often beavers, young and adult rats,[@b134-btt-3-273]--[@b137-btt-3-273] rabbits,[@b138-btt-3-273] dogs,[@b139-btt-3-273] cats,[@b140-btt-3-273] mice,[@b141-btt-3-273],[@b142-btt-3-273] and gerbils.[@b143-btt-3-273],[@b144-btt-3-273] However, the best results have only been obtained in gerbil experimental models. Gerbil (*Meriones unguiculatus*) is considered by several researchers the most appropriate experimental model for giardiasis due to its size, facility to handle, high susceptibility to infections, and large shedding of cysts in their feces.[@b143-btt-3-273]--[@b148-btt-3-273] Thus, we consider that the absence of standardized methods between studies limited the comparative analysis.

When we analyze the studies in human beings (nonrandomized trials and randomized control trials), we find great heterogeneity among them, besides the poor quality of their methodology.

No references selected were similar in design, dosages, duration of treatment, and results, which led to a great difficulty in grouping them according to the tested drug (required time or percentage of fecal cure, independent of duration of treatment). These findings agree with those by Zaat and colleagues.[@b149-btt-3-273]

In the nonrandomized clinical trials, slightly more than a quarter of studies compared the efficacy between drugs, whereas 47.8% tested drugs without comparing them to a placebo or to another drug, just appraising their efficacy in treated patients versus untreated patients. Only 13% compared a drug to a placebo.

On the RCTs, we find that two thirds of the studies (67.6%) compared the efficacy between drugs; however, only 14.7% compared drugs to a placebo. Here, just one study did not include a comparison between drugs. About half the nonrandomized clinical trials tested different dosages of drugs (assessment of therapeutic schemes), whereas the RCTs were comparative studies of efficacy between drugs, with few studies using a placebo for comparing the efficacy of drugs (14.7%).

Regarding the number of drugs tested, we built an extensive list of them: 55 drugs in 39 *in vitro* studies, nine drugs in nine *in vivo* studies, 12 drugs in 23 nonrandomized trials, and 18 drugs in 50 RCTs ([Tables 1](#t1-btt-3-273){ref-type="table"}--[4](#t4-btt-3-273){ref-type="table"}).

Regarding the sample size, in human studies, we found a comparatively small sample size in both nonrandomized and RCTs studies. We found a higher sample size in the RCTs as compared to the nonrandomized studies, though not statistically significant (98.9 × 83.3 patients/study; p \< 0.05).

These findings show a great number of studies in which the external validation, and, consequently, the generalizability of the results is jeopardized. Numerous confounding factors make the analysis of these studies difficult, mainly due to problems in controlling some variables in the population studied.

The most frequently tested drugs in the present review are listed in [Tables 5](#t5-btt-3-273){ref-type="table"}, [6](#t6-btt-3-273){ref-type="table"}, [7](#t7-btt-3-273){ref-type="table"}, and [10](#t10-btt-3-273){ref-type="table"}. We find that the most used drugs in human studies were all tested in *in vitro* studies, but not all drugs tested in *in vivo* studies were tested in human studies, although the number of drugs in the *in vivo* studies was as low as 10 drugs. Metronidazole was the most frequently tested drug. They were tested in 16.4% of *in vitro* studies, in 11.1% of *in vivo* studies, in 39.1% of nonrandomized studies, and in 61.8% of RCTs. Thus, this drug was the main drug in the available arsenal for giardiasis treatment, constituting a reference in relation to other drugs. This finding corroborates other reviews.[@b149-btt-3-273],[@b150-btt-3-273]

When only the nonrandomized and RCTs studies were analyzed, the two most tested drugs were metronidazole and tinidazole. However, mebendazole and albendazole were among the most tested in RCTs, and they were barely tested in nonrandomized studies.

We also noticed that the "new drugs" for giardiasis treatment were barely tested in all categories of studies reviewed in this work, either in *in vitro* studies or in RCTs. This demonstrates the difficulty in adequately testing one drug for giardiasis in order to have alternatives in case of resistance to one of the therapeutic schemes.

In spite of the large amount of drugs used in antigiardial therapy, some resistance has been reported regarding different therapeutic regimens, and this resistance has been mentioned by clinicians.[@b18-btt-3-273],[@b20-btt-3-273],[@b151-btt-3-273] This characteristic makes *Giardia* a fearful microorganism, mainly among undernourished people, in whom the malabsorption syndrome is more common. In this scenario, developing and screening new antigiardial drugs seems to be a priority.

In order to analyze the optimal dosages for the most tested drugs, we evaluated the mean rate of cure for all ([Tables 8](#t8-btt-3-273){ref-type="table"} and [11](#t11-btt-3-273){ref-type="table"}). We found out that the most tested drugs and those with more efficacy in studies with human beings were tinidazole and metronidazole; though ornidazole had a great efficacy not only in nonrandomized but also in RCTs. However, ornidazole was tested in only six studies in the present review (three nonrandomized and three RCTs).

The optimal dosages found in this review for most drugs were those that achieved the best rate of cure for each drug separately. [Tables 8](#t8-btt-3-273){ref-type="table"}, [9](#t9-btt-3-273){ref-type="table"}, [11](#t11-btt-3-273){ref-type="table"}, and [12](#t12-btt-3-273){ref-type="table"} show the most widely used drugs and their mean rate of cure, along with the optimal dosages for each. Comparing the mean rate of cure between the most tested drugs, we detected a similar efficacy among them, none being better than the others, except for mebendazole in the RCTs.

The analyses of the side effects have been poorly appraised and documented in most studies. Apparently, they have been similar in all studies, and no drug was reported to be unsafe, causing only mild to moderate and transient side effects.

However, regarding the new drugs, only those tested in human beings had their side effects described, but we have few data about it at the moment.

In summary, in this review we found many studies on the giardiasis treatment; however, most of them presented various problems concerning the sample size, methodology, design, among others.

Moreover, the number of drugs tested was large, with a relative higher number of new drugs listed, mainly in the *in vitro* studies, and a lower number in the studies with humans. However, these new drugs were barely tested as compared to the old drugs, mainly in humans, increasing the need for new studies to provide standardization for the evaluation of antigiardial drugs. This can provide more accuracy and quickness for approval, as well as an adequate use not only for the new drugs but also the old ones.

Conclusion
==========

In conclusion, this review raises some problems regarding the evidence for using old and new antigiardial drugs, in relation to the quality of previous and future studies. Yet, one must point out that the drugs in use nowadays are the most widely tested and that they are safe, although we must rethink and further study the problem of their increasing resistance.
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###### 

In vitro studies

  Year   Drugs/Substances                                     Activity             Reference
  ------ ---------------------------------------------------- -------------------- ------------------
  1975   2,2-biimidazole                                      Yes                  [@b23-btt-3-273]
  1983   Human milk                                           Yes                  [@b24-btt-3-273]
  1984   Metronidazole                                        Yes                  [@b61-btt-3-273]
         Tinidazole                                           Yes (+ effective)    
         Furazolidone                                         Yes                  
         Quinacrin                                            Yes (− effective)    
  1985   Bithionol                                            Yes                  [@b25-btt-3-273]
         Dichlorophene                                        Yes                  
         Hexachlorophene                                      Yes                  
  1985   Clomipramine                                         Yes                  [@b26-btt-3-273]
  1986   Furazolidone                                         Yes                  [@b27-btt-3-273]
         Nitroimidazole                                       Yes                  
  1990   Azitromicin/Furazolidone                             Yes                  [@b28-btt-3-273]
         Doxiciclin/Mefloquin                                 Yes                  
         Doxiciclin/Tinidazole                                Yes                  
         Mefloquin/Tinidazole                                 Yes                  
  1991   Metronidazole                                        Yes                  [@b29-btt-3-273]
         Ornidazole                                           Yes                  
  1991   Azitromicin                                          Yes                  [@b30-btt-3-273]
  1994   Serum immune specific                                Yes                  [@b31-btt-3-273]
  1994   Agglutinin of wheat germ                             Yes                  [@b32-btt-3-273]
  1994   Derivatives of allicin (diallyl trisulfide)          Yes                  [@b60-btt-3-273]
  1995   Phytotherapics popular in Africa                     Yes (+ effective)    [@b33-btt-3-273]
         Methanolic extracts cathartics                       Yes (− effective)    
         Methanolic extracts noncathartics                                         
  1995   Albendazole                                          Yes (− effective)    [@b34-btt-3-273]
         Metronidazole                                        Yes (+ effective)    
  1999   Derivatives of flavonoid *Helianthenum glomeratum*   Yes                  [@b59-btt-3-273]
  2001   Pyrantel pamoate                                     Yes                  [@b35-btt-3-273]
  2001   Powder of Yucca schidigera                           Yes                  [@b36-btt-3-273]
  2001   Ciprofloxacin                                        Yes                  [@b37-btt-3-273]
  2002   Nitazoxanide                                         Yes (+ effective)    [@b38-btt-3-273]
         Albendazole                                          Yes (+ effective)    
         Metronidazole                                        Yes (− effective)    
  2002   Mucin                                                Yes                  [@b39-btt-3-273]
  2002   Derivatives of isoflavone                            Yes                  [@b40-btt-3-273]
  2003   Derivative etylphenylcarbamate                       Yes (− effective)    [@b41-btt-3-273]
         Albendazole                                          Yes (+ effective)    
  2004   Gangliosides                                         Yes                  [@b42-btt-3-273]
  2004   Derivate phenyl-carbamate                            Yes (- effective)    [@b43-btt-3-273]
         Albendazole                                          Yes (+ effective)    
  2004   S-substituted 4,6-dibromo-mercaptobenzimidazole      Yes                  [@b58-btt-3-273]
         S-substituted 4,6-dichloro-2-mercaptobenzimidazole   Yes                  
  2005   Dodecanoic acid                                      Yes                  [@b44-btt-3-273]
         Metronidazole                                        Yes                  
  2005   Arsenic sodium                                       No                   [@b45-btt-3-273]
  2005   Derivatives of *Artemisia ludoviciana*               Yes                  [@b57-btt-3-273]
  2005   Derivatives of flavonoid glycosides                  Yes                  [@b56-btt-3-273]
  2006   Derivatives benzimidazoles                           Yes (+ effective)    [@b46-btt-3-273]
         Albendazole                                          Yes (++ effective)   
         Metronidazole                                        Yes (− effective)    
  2006   Nitrotiazol (Nitazoxanide)                           Yes                  [@b47-btt-3-273]
         Metronidazole                                        Yes                  
  2006   Venom *Crotalus durissus terrificus*                 Yes                  [@b48-btt-3-273]
         Venom *Bothrops jararaca*                            Yes                  
  2006   Propolis                                             Yes                  [@b49-btt-3-273]
  2006   Curcumin                                             Yes                  [@b50-btt-3-273]
  2006   Metronidazole                                        Yes                  [@b55-btt-3-273]
         Furazolidone                                         Yes (+ effective)    
  2006   *Dorstenia contrajerva*                              Yes                  [@b54-btt-3-273]
         *Senna villosa*                                      Yes                  
         *Ruta chalepensis*                                   Yes                  
  2007   Metronidazole                                        Yes (− effective)    [@b51-btt-3-273]
         Analogous MTZ-Ms                                     Yes                  
         Analogous MTZ-I                                      Yes                  
         Analogous MTZ-Br                                     Yes                  
         Analogous MTZ-N~3~                                   Yes                  
         Analogous MTZ-NH~3~Cl                                Yes                  
  2007   Extracts of blueberry                                Yes                  [@b52-btt-3-273]
  2007   Tiliroside                                           Yes (+ effective)    [@b53-btt-3-273]
         Kaempferol-glucopyranoside                           Yes                  
         Astragalin                                           Yes                  
         Quercitrin                                           Yes                  
         Isoquercitrin                                        No                   

###### 

*In vivo* studies

  Year   Drugs/Substances          Activity            Reference
  ------ ------------------------- ------------------- ------------------
  1991   Albendazole               Yes                 [@b62-btt-3-273]
  1993   New oxadiazoles           Yes (+ effective)   [@b63-btt-3-273]
         Metronidazole             Yes (− effective)   
  1996   Ivermectin                Yes                 [@b64-btt-3-273]
  1998   Disulfiram (Antabuse)     Yes                 [@b65-btt-3-273]
  2000   Oxifendazole              Yes                 [@b66-btt-3-273]
  2001   Ivermectin                Yes                 [@b67-btt-3-273]
  2002   Inmunoglobulin (IgA)      Yes                 [@b68-btt-3-273]
  2003   Vaccine against Giardia   No                  [@b69-btt-3-273]
  2007   Antioxidant (Antox)       No                  [@b70-btt-3-273]

###### 

Nonrandomized clinical trials

  Year   Drugs/Substances                         Activity                               Reference
  ------ ---------------------------------------- -------------------------------------- ------------------
  1972   Berberine                                Yes                                    [@b71-btt-3-273]
  1975   Berberine                                Yes                                    [@b72-btt-3-273]
  1977   Metronidazole                            Yes                                    [@b73-btt-3-273]
         Tinidazole                               Yes                                    
         Nimorazol                                Yes                                    
         Furazolidone                             Yes (− effective)                      
  1978   Tiberal 1 g BID -- G1                    Yes                                    [@b74-btt-3-273]
         Tiberal 50 mg/Kg/single dose -- G2       Yes                                    
                                                  SE \> group G2                         
  1978   Metronidazole in four dosage schedules   Yes (+effective in extended systems)   [@b75-btt-3-273]
  1978   Metronidazole                                                                   [@b76-btt-3-273]
         Tinidazole                               Yes (− effective)                      
                                                  Yes (+ effective)                      
                                                  SE \> with metronidazole               
  1978   Tinidazole                                                                      [@b77-btt-3-273]
         Placebo                                  Yes (+ effective)                      
  1978   Tinidazole single dose highest                                                  [@b78-btt-3-273]
         Tinidazole seven days dose lower         Yes (+ effective)                      
                                                  Yes (− effective)                      
  1979   Metronidazole                                                                   [@b79-btt-3-273]
         Quinacrine                               Yes (+ effective)                      
                                                  Yes (− effective)                      
  1979   Ornidazole                                                                      [@b80-btt-3-273]
                                                  Yes                                    
  1980   Metronidazole seven days                                                        [@b81-btt-3-273]
         Meronidazole single dose                 Yes (− effective)                      
         Quinacrine                               Yes (− effective)                      
         Tinidazole                               Yes (+ effective)                      
         Ornidazole                               Yes (+ effective)                      
                                                  Yes (+ effective)                      
                                                  SE \> with ornidazole                  
  1981   Furazolidone                                                                    [@b82-btt-3-273]
         Quinacrine                               Yes (+ effective)                      
                                                  Yes (− effective)                      
                                                  SE \> with quinacrine                  
  1987   Metronidazole                                                                   [@b83-btt-3-273]
         Tinidazole                               Yes                                    
         Ornidazole                               Yes                                    
                                                  Yes                                    
                                                  Similar efficiencies                   
  1987   Tinidazole                                                                      [@b84-btt-3-273]
  1995   Metronidazole                            Yes                                    [@b85-btt-3-273]
  1997   Metronidazole + diloxanide               Yes                                    [@b86-btt-3-273]
  1997   Pippali Rasayana Placebo                 Yes                                    [@b87-btt-3-273]
                                                  Yes                                    
  1998   Albendazole                                                                     [@b88-btt-3-273]
  1999   Secnidazole                              Yes                                    [@b89-btt-3-273]
  2000   Secnidazole                              Yes                                    [@b90-btt-3-273]
  2008   Metronidazole                            Yes                                    [@b91-btt-3-273]
                                                  Yes                                    

###### 

randomized controlled clinical trials

  Year   Drugs                                     Activity                                                                            Reference
  ------ ----------------------------------------- ----------------------------------------------------------------------------------- -------------------
  1970   Mepacrine                                 --                                                                                  [@b92-btt-3-273]
         Metronidazole                                                                                                                 
         Furazolidone                                                                                                                  
  1977   Tinidazole                                Yes (+ effective and \< SE)                                                         [@b93-btt-3-273]
         Metronidazole                             Yes (− effective and \> SE)                                                         
  1978   Tinidazole                                --                                                                                  [@b94-btt-3-273]
         Metronidazole                                                                                                                 
  1978   Tinidazole                                Yes (+ effective)                                                                   [@b95-btt-3-273]
         Placebo                                                                                                                       
  1981   Tinidazole                                Yes -- Similar efficacy                                                             [@b96-btt-3-273]
         Metronidazole                                                                                                                 
  1985   Tinidazole                                Yes -- Similar efficacy with appropriate doses                                      [@b97-btt-3-273]
         Metronidazole                                                                                                                 
  1989   Furazolidone                              Yes                                                                                 [@b98-btt-3-273]
         Placebo                                                                                                                       
  1989   Metronidazole                             Yes                                                                                 [@b99-btt-3-273]
         Furazolidone                              Yes                                                                                 
  1989   Menbedazole                               No                                                                                  [@b100-btt-3-273]
  1990   Metronidazole                             Yes                                                                                 [@b101-btt-3-273]
         Menbendazole                              Yes                                                                                 
  1991   Metronidazole                             Yes -- Similar efficacy                                                             [@b102-btt-3-273]
         Ornidazole                                                                                                                    
  1992   Metronidazole                             Yes                                                                                 [@b103-btt-3-273]
         Mebendazole                               Yes                                                                                 
  1994   Metronidazole                             Effectiveness of cure similar                                                       [@b104-btt-3-273]
         Albendazole                               SE \> with metronidazole                                                            
  1995   Metronidazole                             Yes                                                                                 [@b105-btt-3-273]
         Albendazole                               Yes                                                                                 
  1995   Bacitracin zinc                           Yes                                                                                 [@b106-btt-3-273]
         Bacitracin                                Yes                                                                                 
         Neomycin                                  Yes                                                                                 
         Neomycin + Bacitracin zinc                Yes                                                                                 
  1995   Metronidazole single dose                 Yes                                                                                 [@b107-btt-3-273]
         Metronidazole for five days               Yes                                                                                 
         Albendazole for five days                 Yes                                                                                 
  1995   Metronidazole                             Yes (effective)                                                                     [@b108-btt-3-273]
         Ornidazole                                Yes (+ effective)                                                                   
         Mebendazole                               Yes (− effective)                                                                   
  1999   Albendazole                               Yes (+ effective)                                                                   [@b109-btt-3-273]
         Tinidazole                                Yes (− effective)                                                                   
  2001   Metronidazole                             Yes                                                                                 [@b110-btt-3-273]
         Mebendazole                               Yes                                                                                 
  2001   Nitazoxanide                              Yes (+ effective)                                                                   [@b111-btt-3-273]
         Placebo                                                                                                                       
  2001   Metronidazole                             Yes -- Similar efficacy                                                             [@b112-btt-3-273]
         Nitazoxanide                                                                                                                  
  2001   Metronidazole + wheat germ                Yes (+ effective)                                                                   [@b113-btt-3-273]
         Metronidazole + Placebo                   Yes (− effective)                                                                   
  2002   Albendazole                               Yes (+ effective)                                                                   [@b114-btt-3-273]
         Albendazole + Praziquantel                Yes (− effective)                                                                   
         Tinidazole                                Yes (+ effective)                                                                   
                                                   Albendazole and Tinidazole with similar effectiveness                               
  2002   Metronidazole                             Yes (− effective)                                                                   [@b115-btt-3-273]
         Ornidazole single dose                    Yes (+ effective)                                                                   
         Ornidazole five days                      Yes (+ effective)                                                                   
  2003   Mebendazole                               Yes                                                                                 [@b116-btt-3-273]
         Secnidazole                               Yes                                                                                 
  2003   Albendazole                               Yes (− effective)                                                                   [@b117-btt-3-273]
         Tinidazole                                Yes (+ effective)                                                                   
         Cloroquine                                Yes (+ effective )                                                                  
                                                   Tinidazole and Cloroquine with similar effectiveness and greater than Albendazole   
  2004   Metronidazole                             Yes                                                                                 [@b118-btt-3-273]
         Albendazole                               Yes                                                                                 
  2004   Metronidazole                             Yes (− effective)                                                                   [@b119-btt-3-273]
         Albendazole                               Yes (+ effective)                                                                   
  2006   Metronidazole + saccharomyces boulardii   Yes (+ effective)                                                                   [@b120-btt-3-273]
                                                   Yes (− effective)                                                                   
         Metronidazole +placebo                                                                                                        
  2006   Mebendazole                               Yes                                                                                 [@b121-btt-3-273]
         Quinacrine                                Yes                                                                                 
  2006   Mebendazole                               Yes (− effective)                                                                   [@b122-btt-3-273]
         Tinidazole                                Yes (+ effective)                                                                   
  2006   Metronidazole                             Yes (− effective)                                                                   [@b123-btt-3-273]
         Albendazole                               Yes (+ effective)                                                                   
  2007   Vitamin A                                 Yes                                                                                 [@b124-btt-3-273]
         Zinc                                      Yes                                                                                 
         Vitamin + zinc                            Yes (+ effective)                                                                   
         Placebo                                   No                                                                                  
  2008   Tinidazole                                Yes (+ effective)                                                                   [@b125-btt-3-273]
         Nitazoxanide                              Yes (− effective)                                                                   

**Abbreviation:** Se, side effects.

###### 

*In vitro* studies: drugs more frequently tested

       Drugs/Substances tested                              Number of studies   Observation
  ---- ---------------------------------------------------- ------------------- --------------------------------------------
  1    2,2-biimidazole                                      1                   --
  2    Human milk                                           1                   --
  3    Bithionol                                            1                   --
  4    Dichlorophene                                        1                   --
  5    Hexachlorophene                                      1                   --
  6    Clomipramine                                         1                   --
  7    Furazolidone                                         4                   [\*](#tfn3-btt-3-273){ref-type="table-fn"}
  8    Nitroimidazole                                       1                   --
  9    Azitromicin                                          2                   [\*](#tfn3-btt-3-273){ref-type="table-fn"}
  10   Doxiciclin                                           1                   --
  11   Mefloquin                                            1                   --
  12   Tinidazole                                           2                   [\*](#tfn3-btt-3-273){ref-type="table-fn"}
  13   Metronidazole                                        9                   [\*](#tfn3-btt-3-273){ref-type="table-fn"}
  14   Ornidazole                                           1                   --
  15   Serum immune specific                                1                   --
  16   Agglutinin of wheat germ                             1                   --
  17   Methanolic extracts cathartics                       1                   [\#](#tfn2-btt-3-273){ref-type="table-fn"}
  18   Methanolic extracts noncathartics                    1                   [\#](#tfn2-btt-3-273){ref-type="table-fn"}
  19   Albendazole                                          5                   [\*](#tfn3-btt-3-273){ref-type="table-fn"}
  20   Pyrantel pamoate                                     1                   --
  21   Powder of *Yucca schidigera*                         1                   --
  22   Ciprofloxacin                                        1                   --
  23   Nitazoxanide (Nitrotiazol)                           2                   [\*](#tfn3-btt-3-273){ref-type="table-fn"}
  24   Mucin                                                1                   --
  25   Derivatives of isoflavone                            1                   --
  26   Derivative etylphenylcarbamate                       2                   [\*](#tfn3-btt-3-273){ref-type="table-fn"}
  27   Gangliosides                                         1                   --
  28   Dodecanoic acid                                      1                   --
  29   Arsenic sodium                                       1                   --
  30   Derivatives benzimidazoles                           1                   --
  31   Venom *Crotalus durissus terrificus*                 1                   --
  32   Venom *Bothrops jararaca*                            1                   --
  33   Propolis                                             1                   --
  34   Curcumin                                             1                   --
  35   Analogous MTZ-Ms                                     1                   --
  36   Analogous MTZ-I                                      1                   --
  37   Analogous MTZ-Br                                     1                   --
  38   Analogous MTZ-N~3~                                   1                   --
  39   Analogous MTZ-NH~3~Cl                                1                   --
  40   Extracts of blueberry                                1                   --
  41   Tiliroside                                           1                   --
  42   Kaempferol-glucopyranoside                           2                   [\*](#tfn3-btt-3-273){ref-type="table-fn"}
  43   Astragalin                                           1                   --
  44   Quercitrin                                           1                   --
  45   Isoquercitrin                                        1                   --
  46   Dorstenia contrajerva                                1                   --
  47   Senna villosa                                        1                   --
  48   Ruta chalepensis                                     1                   --
  49   Derivatives of flavonoid glycosides                  1                   --
  50   Derivatives of *Artemisia ludoviciana*               1                   --
  51   S-substituted 4,6-dibromo mercaptobenzimidazole      1                   --
  52   S-substituted 4,6-dichloro-2-mercaptobenzimidazole   1                   --
  53   Derivatives of flavonoid Helianthenum glomeratum     1                   --
  54   Derivatives of allicin (diallyl trisulfide)          1                   --
  55   Quinacrin                                            1                   --

**Notes:** phytotherapies are popular in Africa;

Drugs more frequently tested.

###### 

*In vivo* studies: drugs more frequently tested

      Drugs tested              Number of studies   Observation
  --- ------------------------- ------------------- --------------------------------------------
  1   Albendazole               1                   --
  2   News oxadiazoles          1                   --
  3   Metronidazole             1                   --
  4   Ivermectin                2                   [\*](#tfn4-btt-3-273){ref-type="table-fn"}
  5   Disulfiram (Antabuse)     1                   --
  6   Oxifendazole              1                   --
  7   Inmunoglobulin (IgA)      1                   --
  8   Vaccine against Giardia   1                   --
  9   Antioxidant (Antox)       1                   --

**Note:** Drugs more frequently tested.

###### 

Drugs more frequently tested in nonrandomized clinical trials

       Drugs tested       Number of studies   Observation
  ---- ------------------ ------------------- --------------------------------------------
  1    Berberine          2                   [\*](#tfn5-btt-3-273){ref-type="table-fn"}
  2    Metronidazole      9                   [\*](#tfn5-btt-3-273){ref-type="table-fn"}
  3    Tinidazole         7                   [\*](#tfn5-btt-3-273){ref-type="table-fn"}
  4    Nimorazole         1                   --
  5    Furazolidone       2                   [\*](#tfn5-btt-3-273){ref-type="table-fn"}
  6    Tiberal            1                   --
  7    Quinacrin          3                   [\*](#tfn5-btt-3-273){ref-type="table-fn"}
  8    Ornidazole         3                   [\*](#tfn5-btt-3-273){ref-type="table-fn"}
  9    Diloxanide         1                   --
  10   Pippali Rasayana   1                   --
  11   Albendazole        1                   --
  12   Secnidazole        2                   [\*](#tfn5-btt-3-273){ref-type="table-fn"}

**Note:** Drugs more frequently tested.

###### 

Mean rate of cure of drugs more tested in nonrandomized clinical trials

      Drugs tested    Number of studies   Mean rate of cure % ± SD (CI)
  --- --------------- ------------------- -------------------------------
  1   Metronidazole   9                   76.6 ± 20.6 (64.9--88.3)
  2   Tinidazole      7                   89.1 ± 8.8 (83--92.5)
  3   Ornidazole      3                   93.6 ± 1.2 (92.2--95)
  4   Quinacrin       3                   85 ± 21.6 (63.8--100)
  5   Secnidazole     2                   96 ± 2.8 (92.0--99.9)
  6   Furazolidone    2                   82 ± 14.0 (62.5--100)

**Note:** Drugs more frequently tested.

**Abbreviations:** CI, confidence interval; SD, standard deviation.

###### 

More effective doses of drugs tested in nonrandomized clinical trials

  Drugs           Unit        Recommended doses
  --------------- ----------- ------------------------------
  Metronidazole   mg/Kg/day   15--25 TID -- 5 to 10 days
                  mg          200--500 TID -- 5 to 10 days
  Tinidazole      mg          1--2 MID -- One day
  Ornidazole      mg          2 MID -- One day
  Quinacrine      mg          100 TID -- 5 days
  Secnidazole     mg/Kg       30 MID -- One day

**Abbreviations:** TID, three times a day; MID, once a day.

###### 

Drugs more frequently tested in randomized control clinical trials

       Drugs tested              Number of studies   Observation
  ---- ------------------------- ------------------- --------------------------------------------
  1    Mepacrine                 1                   --
  2    Metronidazole             21                  [\*](#tfn9-btt-3-273){ref-type="table-fn"}
  3    Furazolidone              3                   [\*](#tfn9-btt-3-273){ref-type="table-fn"}
  4    Tinidazole                10                  [\*](#tfn9-btt-3-273){ref-type="table-fn"}
  5    Mebendazole               8                   [\*](#tfn9-btt-3-273){ref-type="table-fn"}
  6    Ornidazole                3                   [\*](#tfn9-btt-3-273){ref-type="table-fn"}
  7    Albendazole               9                   [\*](#tfn9-btt-3-273){ref-type="table-fn"}
  8    Bacitracin zinc           1                   --
  9    Neomycin                  1                   --
  10   Nitazoxanide              3                   [\*](#tfn9-btt-3-273){ref-type="table-fn"}
  11   Wheat germ                1                   --
  12   Praziquantel              1                   --
  13   Cloroquine                1                   --
  14   Secnidazole               1                   --
  15   Saccharomyces boulardii   1                   --
  16   Quinacrin                 1                   --
  17   Vitamin A                 1                   --
  18   Zinc                      2                   --

**Note:** Drugs more frequently tested.

###### 

Mean rate of cure of drugs in randomized control clinical trials

      Drugs tested    Number of studies   Mean rate of cure % ± SD (CI)
  --- --------------- ------------------- -------------------------------
  1   Metronidazole   21                  81.5 ± 18.6 (71.0--92.0)
  2   Tinidazole      10                  91.1 ± 6.3 (87.2--95.0)
  3   Albendazole     9                   73.4 ± 19.8 (58.7--88.1)
  4   Mebendazole     8                   65.6 ± 17.3 (50.4--80.8)
  5   Ornidazole      3                   97.6 ± 2.5 (95.4--99.8)
  6   Nitazoxanide    3                   79.7 ± 1.8 (77.2--82.2)

**Note:** Drugs more frequently tested.

**Abbreviations:** CI, confidence interval; SD, standard deviation.

###### 

More effective doses of drugs tested in randomized clinical trials

  Drugs           Unit        Recommended doses
  --------------- ----------- ------------------------------
  Metronidazole   mg/Kg/day   15--50 TID -- 5 to 10 days
                  mg          500--750 TID -- 5 to 10 days
  Tinidazole      mg          2 MID -- One dose
                  mg/Kg/day   50 MID -- One dose
  Albendazole     mg          400 MID -- One day
                  mg          400 MID -- 5 days
                  mg/Kg/day   10 MID -- 5 days
  Mebendazole     mg          200 TID -- 5 days
  Ornidazole      mg/Kg/day   20--40 MID -- 1 to 5 days
  Nitazoxanide    mg          500 MID -- 3 days

**Abbreviations:** TID, three times a day; MID, once a day.
